中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

61 records (took 0.023 seconds)

    A1 adenosine receptor antagonist for preventing and treating tissue injury and sepsis associated with yersinia pestis infection
    53.
    发明公开
    A1 adenosine receptor antagonist for preventing and treating tissue injury and sepsis associated with yersinia pestis infection 审中-公开
    A 1腺苷受体拮抗剂，其用于与所述Versinia菌感染连接预防和治疗组织损伤和败血症

    公开(公告)号：EP2036562A1

    公开(公告)日：2009-03-18

    申请号：EP08252607.0

    申请日：2008-07-31

    Applicant: Endacea, Inc.

    Inventor： Wilson, Constance N.

    IPC: A61K31/522 ,  A61P31/04

    CPC classification number: A61K31/522 ,  Y02A50/406

    Abstract: Methods for treating and preventing tissue injury and sepsis associated with a Yersinia pestis infection, particularly pneumonic plague, are provided. The methods of the invention comprise administering to a subject a therapeutically effective amount of an A 1 adenosine receptor antagonist alone or in combination with at least one additional therapeutic agent, including an antibiotic agent. The present methods find use in biodefense as a means of preventing and treating tissue injury and sepsis associated with Y. pestis infection, particularly pneumonic plague, in the event of a bioterrorist attack with this deadly bacterium.

    Abstract translation: 用于治疗和预防与鼠疫耶尔森氏菌感染，特别是肺鼠疫相关的组织损伤和脓毒病的方法中，提供了。 本发明的方法包括给予受试者治疗有效量的A 1个腺苷受体拮抗剂单独或与至少一种另外的治疗剂组合，包括抗生素剂。 本发明的方法发现的生物防御用途预防和治疗与鼠疫菌感染，特别是肺鼠疫相关的组织损伤和败血症，在生物恐怖袭击与这种致命细菌的情况下的一种手段。

    COMPOSITIONS AND METHODS FOR TREATING RESPIRATORY DISORDERS
    54.
    发明公开
    COMPOSITIONS AND METHODS FOR TREATING RESPIRATORY DISORDERS 审中-公开
    组合物和方法的呼吸问题的治疗

    公开(公告)号：EP2001881A2

    公开(公告)日：2008-12-17

    申请号：EP07758067.8

    申请日：2007-03-07

    Applicant: Endacea, Inc.

    Inventor： WILSON, Constance, N. ,  PARTRIDGE, John, J.

    IPC: C07D473/04 ,  A61K31/52 ,  A61P11/00

    CPC classification number: C07D473/04 ,  A61K31/522 ,  C07D473/06

    Abstract: Methods and compositions for treating and preventing respiratory disorders are provided. The methods of the invention comprise administering to a subject a therapeutically effective amount of a pharmaceutically acceptable salt of an A1 adenosine receptor antagonist, particularly 1-hydroxy-2-naphthoic acid salts or 3- hydroxy-2-naphthoic acid salts, more particularly a 1-hydroxy-2-naphthoic acid salt of 3-[2-(4-aminophenyl)ethyl]-8-benzyl-7- {2-[ethyl-(2-hydroxyethyl)amino]ethyl} - 1 propyl-3,7-dihydropurine-2,6-dione (i.e., an L-97-1 xinafoic acid salt). Hydrates of the A1 adenosine receptor antagonist salts described herein are further provided. The invention further encompasses pharmaceutical compositions comprising a pharmaceutically acceptable salt of an A1 adenosine receptor antagonist in a pharmaceutically acceptable carrier. The compositions of the invention find use in methods for treating and preventing respiratory disorders.

    A1 ADENOSINE RECEPTOR ANTAGONISTS
    56.
    发明公开
    A1 ADENOSINE RECEPTOR ANTAGONISTS 审中-公开
    A1腺苷受体拮抗剂

    公开(公告)号：EP2222676A2

    公开(公告)日：2010-09-01

    申请号：EP08867973.3

    申请日：2008-12-19

    Applicant: Endacea, Inc.

    Inventor： WILSON, Constance, N.

    IPC: C07D473/14 ,  C07D473/02

    CPC classification number: C07D473/06

    Abstract: This invention relates to compounds of formula (I), Wherein R
    1 - R
    4 are defined in the Specification, their uses in the practice of medicine, their medicinal formulations, their use in medical diagnosis, and their preparation.

    Abstract translation: 本发明涉及式（I）化合物，其中R 1 -R 4在说明书中定义，它们在医学实践中的用途，它们的药物制剂，它们在医学诊断中的用途以及它们的制备。

Patent Agency Ranking